• / Free eNewsletters & Magazine
  • / My Account
Home>Lysogene Announces Company Presentations at October & November Investor Conferences

Lysogene Announces Company Presentations at October & November Investor Conferences

Lysogene Announces Company Presentations at October & November Investor Conferences

10/04/2017

Lysogene Announces Company Presentations at October & November Investor Conferences

Regulatory News:

Lysogene (Paris:LYS) (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in the following investor events in the upcoming weeks:

October

  • Chardan Gene Therapy Conference (New York, US)
Date:       Wednesday, October 11
Time: 3:45pm Eastern Time
Location: Westin New York Grand Central, Assembly Room
  • Jefferies Gene Editing & Gene Therapy Summit (New York, US)
Date:       Thursday, October 12
Time: 2:30pm Eastern Time
Location: Westin New York Grand Central
  • Key Opinion Leader Lunch: Gene Therapy for Patients with Sanfilippo Syndrome Type A (MPS IIIA) (New York, US)
Date:       Friday, October 13
Time: 12:00pm – 1:30pm Eastern Time
Location: Lotte New York Palace Hotel

Webcast: http://lifesci.rampard.com/20171013/reg.jsp

November

  • Jefferies 2017 London Healthcare Conference (London, UK)
Date:       Tuesday, November 14 & Wednesday, November 15
Time: TBD
Location: Waldorf Hilton

About Lysogene

Lysogene (www.lysogene.com) is a global biopharma leader in orphan CNS disease research and development. Lysogene has generated five non-cumulative years of clinical safety data to show the efficiency of a direct delivery route to the CNS with its initial gene therapy trial for MPS IIIA. Lysogene has recently completed the enrollment for the first multi-national observational study in MPS IIIA which will function as the non-concurrent control for the first pivotal trial for MPS IIIA in H1 2018. Lysogene also plans a clinical trial for GM1 Gangliosidosis for 2019. Lysogene has obtained orphan drug designation from the EMA and FDA and rare pediatric designation by the FDA for both programs.

©2017 Morningstar Advisor. All right reserved.